Laquinimod Disappoints Again, This Time In Huntington's Disease
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
You may also be interested in...
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Further details of a Phase I/II study results are raising hopes that it could be the first disease-modifying treatment for the disease, but it is not yet known whether the reduction in Huntintin seen will translate into a clinical benefit.